Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists

Cancer Gene Therapy

Volumn 18, Issue 12, 2011, Pages 850-858

  Triozzi, P L ^a   Aldrich, W ^a   Ponnazhagan, S ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

dendritic cells; myeloid suppressor cells; regulatory T cells; T helper cells; Toll like receptors

Indexed keywords

ADENO ASSOCIATED VIRUS CARCINOEMBRYONIC ANTIGEN VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; OLIGODINUCLEOTIDE 1826; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LINE; COLON CANCER; CONTROLLED STUDY; HELPER CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY;

AMINOQUINOLINES; ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DENDRITIC CELLS; DEPENDOVIRUS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, HELPER-INDUCER; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; VACCINES, SYNTHETIC;

ADENO-ASSOCIATED VIRUS; MUS; MUS MUSCULUS;

EID: 81155130926     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.54     Document Type: Article

References (50)

1. Ponnazhagan S. Adenoassociated virus vectors for genetic immunization. Immunol Res 2002; 26: 247-253. (Pubitemid 35177501)
2. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425. (Pubitemid 30091497)
3. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Therapy 2005; 12: 1453-1464. (Pubitemid 41486134)
4. Zhang TP, Jin DY, Wardrop III RM, Gui T, Maile R, Frelinger JA et al. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Therapy 2007; 14: 429-440.
5. Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther 2004; 15: 856-864. (Pubitemid 39244840)
6. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-2656.
7. Triozzi PL, Aldrich W, Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine 2010; 28: 7837-7843.
8. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003; 9: 1837-1849. (Pubitemid 36554612)
9. Mizobata S, Tompkins K, Simpson JF, Shyr Y, Primus FJ. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000; 49: 285-295. (Pubitemid 30615042)
10. Zhou H, Luo Y, Mizutani M, Mizutani N, Becker JC, Primus FJ et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigenbased DNA minigene vaccines. J Clin Invest 2004; 113: 1792-1798. (Pubitemid 39071671)
11. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 2007; 120: 585-593. (Pubitemid 44969030)
12. Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4f T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006; 63: 35-41.
13. Saha A, Bhattacharya-Chatterjee M, Foon KA, Celis E, Chatterjee SK. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer 2009; 124: 877-888.
14. Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 2006; 55: 515-527.
15. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998; 58: 1469-1477. (Pubitemid 28193610)
16. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloidderived suppressor cell function. J Exp Med 2006; 203: 2691-2702. (Pubitemid 44833345)
17. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006; 177: 3260-3265. (Pubitemid 44277845)
18. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 2006; 17: 81-92. (Pubitemid 43100517)
19. Sharma S, Karakousis CP, Takita H, Shin K, Brooks SP. Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN. Neoplasia 2004; 6: 523-528. (Pubitemid 39411088)
20. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol 2008; 83: 1136-1144. (Pubitemid 351960345)
21. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654. (Pubitemid 41113195)
22. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-337. (Pubitemid 41716769)
23. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008; 14: 3156-3167.
24. Kurts CJ, Miller FAP, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class Irestricted cross presentation is biased toward high-dose antigens and those released during cellular destruction. J Exp Med 1998; 188: 409-414. (Pubitemid 28357770)
25. Nelson D, Bundell C, Robinson B. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. J Immunol 2000; 165: 6123-6132.
26. Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, La Monica N. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 2009; 16: 462-472.
27. Ullenhag GJ, Frö din JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colonystimulating factor. Clin Cancer Res 2004; 10: 3273-3281. (Pubitemid 38685431)
28. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733-3737.
29. Kelly ME, Zhuo J, Bharadwaj AS, Chao H. Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther 2009; 17: 857-863.
30. Ehlers M, Ravetch JV. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol 2007; 28: 74-79. (Pubitemid 46176735)
31. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005; 25: 29-40. (Pubitemid 40386176)
32. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175: 5601-5605. (Pubitemid 41508038)
33. Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Slavin S. CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. Biol Blood Marrow Transplant 2008; 14: 973-984.
34. Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4fCD25+ T regulatory cells. J Leukoc Biol 2010; 87: 117-125.
35. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68: 8446-8455.
36. Elia L, Aurisicchio L, Facciabene A, Giannetti P, Ciliberto G, La Monica N et al. CD4fCD25+ regulatory T-cellinactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther 2007; 14: 201-210. (Pubitemid 46106963)
37. Dietrich A, Stockmar C, Aust G, Endesfelder S, Guetz A, Sack U et al. Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. J Cancer Res Clin Oncol 2006; 132: 379-388.
38. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16: 1812-1823.
39. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752. (Pubitemid 37494166)
40. Nausch N, Galani IE, Schlecker E, Cerwenka A. Mononuclear myeloid-derived 'suppressor' cells express RAE-1 and activate natural killer cells. Blood 2008; 112: 4080-4089.
41. Bergami-Santos PC, Mariano M, Barbuto JA. Dual role of polymorphonuclear neutrophils on the growth of Ehrlich ascites tumor (EAT) in mice. Life Sci 2004; 75: 245-255. (Pubitemid 38553879)
42. Vicari AP, Chiodoni C, Vaure C, Ä t-Yahia S, Dercamp C, Matsos F et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-549.
43. Melencio L, McKallip RJ, Guan H, Ramakrishnan R, Jain R, Nagarkatti PS et al. Role of CD4(f)CD25(r) T regulatory cells in IL-2-induced vascular leak. Int Immunol 2006; 18: 1461-1471. (Pubitemid 44446824)
44. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-366.
45. Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005; 174: 6692-6701. (Pubitemid 40705631)
46. Chen CJ, Shively JE. The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and downregulates IL-2 receptor. J Immunol 2004; 172: 3544-3552. (Pubitemid 38337935)
47. Nonaka M, Ma BY, Murai R, Nakamura N, Baba M, Kawasaki N et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol 2008; 180: 3347-3356.
48. Tassi E, Gavazzi F, Albarello L, Senyukov V, Longhi R, Dellabona P et al. Carcinoembryonic antigen-specific but not antiviral CD4f T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 2008; 181: 6595-6603.
49. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002; 20: 2197-2207. (Pubitemid 34408812)
50. Murad YM, Clay TM. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 2009; 23: 361-375.